Code Biotherapeutics Stock

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

Sign up today and learn more about Code Biotherapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Code Biotherapeutics Stock

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Funding History

April 2021$10.0M
June 2022$75.0M

Management

COO

Erin Brubaker

Chairman, Chief Executive Officer, and Co-Founder

Brian McVeigh

Board Member

Joseph Truitt

Chief Scientific Officer

David Anderson

Chief Technology Officer and Co-Founder

Robert Getts

Chief Business Officer

Lauren Kaskiel

Board Member

Ed Mathers

Board Member

Diana Bernstein

Board Member

Kathy Rouan

Board Member

Rob Lin

Board Member

Russ Fein

VP Preclinical and Process Development; Co-Founder

Lori Getts

Board Member

Victor Stone

Board Member

Dmitry Kuzmin

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo